Loading
A phase 3 trial of anlotinib and etoposide in lung cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.
A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy is a phase 3, interventional study registered as NCT07728955 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 64 participants, started 2026-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: benmelstobart in combination with anlotinib and etoposide. Conditions listed: Small Cell Lung Cancer ( SCLC ). Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Intensive treatment is defined as first-line intensive therapy for metastatic small cell lung cancer, i". No results are recorded here; the registry entry is the source.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Anlotinib, Etoposide, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Etoposide, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.